{"entity":{"id":"nct06380660","kind":"trial","name":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ACE-86225106 tablet in ovarian cancer and prostate cancer, run by Acerand Therapeutics (Shanghai) Limited, active and no longer recruiting.","summary":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06380660 by Acerand Therapeutics (Shanghai) Limited, with 298 participants enrolled, started 2024-03-22 and due to reach its primary completion in 2028-12-21. Interventions recorded: ACE-86225106 tablet.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06380660","url":"https://clinicaltrials.gov/study/NCT06380660"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06380660","phase":"1/2","setting":"A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Acerand Therapeutics (Shanghai) Limited","enrolled":298,"outcomes":[]},"route":"/trials/nct06380660/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}